Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2023

Availability of Transgene’s 2022 Universal Registration Document

Availability of Transgene’s 2022 Universal Registration Document 15

Published 6 April 2023
Categorized as 2023, dates, dates, Press release, TG4050

Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers

Transgene to host KOL webinar on TG4050 15

Published 4 April 2023
Categorized as 2023, dates, dates, Press release, TG4050

Transgene Announces Upcoming Investor Meetings

Transgene announces upcoming investor meetings 15

Published 27 March 2023
Categorized as 2023, dates, dates, Press release

Positive data on key clinical candidates delivered in 2022 – Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum

2022 full-year results and business update 15

Published 16 March 2023
Categorized as 2023, dates, dates, Press release

Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023

Transgene to present multiple posters highlighting the potential of its exciting immunotherapy pipeline at AACR2023 15

Published 15 March 2023
Categorized as 2023, dates, Press release, TG4001, TG4050, TG6002, TG6050-en

Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors

Transgene appoints John C Bell and Pedro Romero as Key Scientific advisors 15

Published 9 March 2023
Categorized as 2023, dates, dates, Press release

Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration

Transgene recieves approval to start a Phase I trial of TG6050 15

Published 6 January 2023
Categorized as 2023, categorie-orpheline, dates, Invir.IO, Press release, TG6050-en

Transgene announces Financial Calendar for 2023

Transgene announces Financial Calendar for 2023 15

Published 4 January 2023
Categorized as 2023, dates, Invir.IO, Press release, TG6002

Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers

C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication

Published 30 September 2019
Categorized as -others, 2023, Publication, TG4001, TG4001

Posts pagination

Newer posts Page 1 … Page 4
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu